Transmedics Group Inc [TMDX] stock is trading at $104.01, down -0.04%. An important factor to consider is whether the stock is rising or falling in short-term value. The TMDX shares have lost -10.89% over the last week, with a monthly amount drifted -12.45%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on September 04, 2025, when Stifel initiated its Hold rating and assigned the stock a price target of $115. Previously, JP Morgan downgraded its rating to Neutral on December 17, 2024, and dropped its price target to $75. On November 22, 2024, downgrade downgraded it’s rating to Hold. Oppenheimer reiterated its Outperform rating and decreased its price target to $125 on October 29, 2024. Needham reiterated its recommendation of a Buy and reduced its price target to $109 on October 29, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on September 24, 2024, and assigned it a price target of $200. In a note dated August 21, 2024, Needham initiated a Buy rating and provided a target price of $208 on this stock.
Transmedics Group Inc [TMDX] stock has fluctuated between $55.00 and $169.29 over the past year. Currently, Wall Street analysts expect the stock to reach $111.75 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $104.01 at the most recent close of the market. An investor can expect a potential return of 7.44% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
Transmedics Group Inc [NASDAQ:TMDX] reported sales of 531.29M for the trailing twelve months, which represents a growth of 37.68%. Gross Profit Margin for this corporation currently stands at 0.6% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.14%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.28 and Total Capital is 0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.63.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 101.42 points at the first support level, and at 98.84 for the second support level. However, for the 1st resistance point, the stock is sitting at 106.17, and for the 2nd resistance point, it is at 108.33.
Ratios To Look Out For
For context, Transmedics Group Inc’s Current Ratio is 9.86. On the other hand, the Quick Ratio is 9.17, and the Cash Ratio is 7.07. Considering the valuation of this stock, the price to sales ratio is 6.67, the price to book ratio is 11.13 and price to earnings (TTM) ratio is 53.79.
Transactions by insiders
Recent insider trading involved Hassanein Waleed H, President & CEO, that happened on Aug 06 ’25 when 8400.0 shares were purchased. President & CEO, Hassanein Waleed H completed a deal on Aug 07 ’25 to buy 8475.0 shares. Meanwhile, Director Basile Edward M sold 4143.0 shares on Aug 04 ’25.
